Diaflex

Quick links to important sections

Diaflex

Method of action: Anti-Inflammatory, Antirheumatic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diaflex

Quick Facts

Property Description
Active Ingredient Diacerein
Form Capsules
Pharmacological Class Symptomatic Slow-Acting Drug for Osteoarthritis (SySADOA)
Common Use Management of Osteoarthritis symptoms
Origin Synthetic Anthraquinone Derivative

Diaflex: A Targeted Symptomatic Slow-Acting Drug

Diaflex is a brand of prescription-only medicine administered orally, containing the active substance Diacerein. It is classified as a Symptomatic Slow-Acting Drug for Osteoarthritis (SySADOA), a therapeutic class intended for the long-term, progressive management of symptoms associated with degenerative joint diseases. Pharmacological studies have evaluated the clinical efficacy of Diacerein, describing its potential to improve function and reduce persistent joint discomfort. This slow-acting nature means the medication's primary benefit is gradual and sustained, which is typical for managing a chronic condition like osteoarthritis.

Diacerein: Composition and Unique Origin

The core component, Diacerein (INN), is chemically a synthetic anthraquinone derivative. Diaflex is typically presented in capsules for systemic delivery, functioning as a single active ingredient product. Diacerein acts as a prodrug, meaning it converts completely into its therapeutically active metabolite, rhein, after ingestion. This focused activity provides an anti-catabolic action, which is recognized for helping to mitigate the process of cartilage degradation within the joints by inhibiting the pro-inflammatory messenger protein, Interleukin-1 beta (IL-1β).

Key Therapeutic Role of This Class

The unique therapeutic contribution of Diaflex lies in its ability to influence the chronic pathology of osteoarthritis itself. By addressing the inflammatory pathways that drive the breakdown of joint tissue, the medication provides long-term, structural support to the joint environment. This sustained, internal effect is distinct from the temporary relief offered by common analgesics, establishing Diacerein as a foundational oral component in the comprehensive management strategy for degenerative joint diseases.

What side effects are possible with Diaflex?

Side Effects and Safety Information for Diaflex

The safety profile for Diaflex, a combination product used for osteoarthritis, is primarily characterized by effects involving the gastrointestinal system and specific patient-based restrictions.

Adverse Reactions

Adverse reactions associated with the use of Diaflex include effects classified as Common in regulatory reporting frameworks. These most frequently reported reactions are:

  • Nausea
  • Diarrhea
  • Constipation
  • Indigestion and Heartburn
  • Urine discoloration
  • Drowsiness
  • Headache
  • Skin reactions
  • Increased intraocular pressure (due to the presence of glucosamine)

Most common side effects often resolve as the body adapts to the medication.

Safety Restrictions and Precautions

Liver and Hepatic Function: Diaflex is generally considered unsafe for use in individuals with pre-existing liver disease (hepatic impairment) and should be avoided in this population. The product contains components, such as Diacerein, that require caution regarding liver function.

Kidney Function: Limited available data suggests that Diaflex is likely safe for use in patients with kidney disease (renal impairment), and dose adjustment may not be necessary. However, caution is advised for all patients with renal issues.

Metabolic and Ocular Considerations: Caution is advised for patients with diabetes mellitus due to the potential for the product's components to affect blood sugar levels and worsen insulin resistance. Patients with a history of ocular hypertension should be monitored due to the risk of increased intraocular pressure.

Driving and Alcohol: It is not definitively known whether Diaflex impairs the ability to drive or operate heavy machinery. Patients who experience symptoms affecting concentration or reaction time should not drive. Caution is also advised regarding the concurrent consumption of alcohol.

General Safety Context

The overall safety profile highlights the need for particular caution in patients with hepatic impairment and those with specific metabolic or ocular conditions. Physicians may monitor liver function and blood glucose levels during treatment.

Overdose and Emergency Response

Diaflex Overdose and When to Seek Help

The overdose profile for Diaflex is defined by an exaggeration of its known effects, as documented in government regulatory sources.

Documented Overdose Manifestations

The most commonly documented manifestation following overdose is the occurrence of profuse diarrhea accompanied by abdominal pain. The primary acute risk arising from this is the progression to severe dehydration and subsequent disorders of fluid and electrolyte balance, which can lead to life-threatening complications.

Regulators also document the potential for severe outcomes related to the liver, including acute liver injury and hepatitis. In the event of an overdose, management is restricted to symptomatic and supportive treatment, as no specific antidote is known. This includes procedural steps focused on the correction of any severe fluid or electrolyte loss.

When Urgent Medical Attention is Required

Regulatory guidelines mandate specific actions to be taken in severe situations. Patients must immediately contact a physician upon the appearance of symptoms suggestive of serious hepatic involvement, such as jaundice (yellowing of the skin or eyes), new or worsening abdominal pain, or impaired consciousness. Furthermore, treatment with Diaflex must be stopped if severe diarrhea occurs. Authorities note that elderly patients face increased vulnerability to serious complications, particularly those related to diarrhea-induced fluid and electrolyte disturbances.

Therapeutic Uses of Diaflex

What Diaflex Treats: Main Uses and Benefits

Diaflex is considered relevant for easing symptom clusters that may become intense or disruptive during temporary flare-ups. It may be part of symptomatic management applied in clinical settings that involve acute or unstable symptom patterns related to musculoskeletal conditions. Its core therapeutic domain is commonly used to help with supportive symptom management for both symptoms related to physical discomfort and symptoms of increased neurological or muscular activity that create noticeable physiological strain.

The treatment is relevant when supportive symptom management is appropriate for symptoms of increased neurological or muscular activity associated with acute or episodic changes. This approach is relevant for easing symptoms that interfere with daily comfort, including symptoms related to physical discomfort and increased neurological or muscular activity. The combination is applied in addressing conditions presenting with systemic or localized discomfort and symptoms related to inflammatory or irritative states. The combined approach contributes to easing the overall symptom load and may assist with maintaining functional stability, which may help patients cope more steadily with symptom fluctuations.

“The combined approach may assist with maintaining functional stability, which may help patients cope more steadily with symptom fluctuations.”

Quick Fact: Relevant for Easing Symptoms related to physical discomfort

Eligibility and Restrictions for Use

Who can and cannot use Diaflex?

The use of Diaflex (Diacerein) is defined by strict regulatory eligibility rules that specify which populations may use the medicine and which are absolutely excluded.

Populations Who Must Not Use Diaflex (Contraindications):

Use is absolutely prohibited for any patient with a current or history of liver disease. It is also strictly contraindicated in individuals with inflammatory organic bowel disease (such as Crohn’s disease or Ulcerative Colitis), intestinal obstruction, or hypersensitivity to diacerein or its active metabolite, rhein. Patients with certain metabolic disorders, like congenital galactosemia, must also not use this medicine.

Age and Restricted Use:

Diaflex is generally limited to adults aged 15 years and older and should not be administered to children under 15 years of age. Furthermore, use is not recommended for patients aged 65 years and above due to regulatory concerns.

Condition-Based Eligibility:

The medicine is restricted to treating osteoarthritis of the hip or knee, and is not recommended for rapidly progressive hip osteoarthritis. Patients with severe renal insufficiency (C cr < 30 ml/min) must use the medicine with a mandatory reduction in their daily dosage. Use is also not recommended during pregnancy or lactation.

What should I know about interactions with other medicines?

Diaflex Interactions with Other Medicines and Products

Regulatory information defines the interaction profile of Diaflex (Diacerein) based on pharmacokinetic effects, pharmacodynamic risks, and restrictions on co-administered substances. This profile is structured to manage risks related to absorption and electrolyte balance.


Documented Pharmacological Interactions

Interaction Type Interacting Substance(s) Official Regulatory Statement
Contraindicated Laxatives Formal prohibition of co-administration due to the additive risk of severe diarrhea.
PK (Absorption) Antacids (Aluminum/Magnesium salts) Decreased digestive absorption of Diacerein.
PD (Cardiac Risk) Diuretics (Loop and Thiazides) & Cardiac Glycosides (e.g., Digoxin) Caution required due to increased risk of arrhythmia secondary to hypokalemia, which may result from Diacerein-induced diarrhea.

Administration Timing and Substance Restrictions

Administration of Antacids must be performed separately from Diaflex, with official regulatory guidance recommending an interval of greater than 2 hours to manage the decrease in absorption. The systemic exposure (bioavailability) of Diacerein is officially documented to increase by 25% when taken with a main meal.

Patients are advised to limit their alcohol intake due to the caution associated with the use of other products that carry a risk of hepatic injury. Furthermore, the use of Diaflex is contraindicated in any patient with current or past liver disease.

Mechanism of Action

How Diaflex Works: Pharmacodynamic Mechanism

Diaflex operates via dual, complementary mechanistic domains within the joint system: anti-catabolism and pro-anabolism.

The anti-catabolic mechanism involves the active metabolite of Diacerein specifically acting as an inhibitor of Interleukin-1 beta (IL-1beta) signaling. This targeted interaction suppresses the activity and expression of destructive enzymes, such as metalloproteinases, resulting in the modulation of the rate of cartilage matrix degradation.

Concurrently, the pro-anabolic mechanism uses Glucosamine as an essential precursor. Glucosamine supplies amino sugars that support chondrocytes in the synthesis of complex structural macromolecules, including proteoglycans and glycosaminoglycans. This enhances the production and incorporation of structural components into the cartilage matrix.

The third component, Methyl Sulfonyl Methane (MSM), influences the local environment by acting as an antioxidant, mitigating reactive oxygen species (ROS) and modulating inflammatory transcription factors like NF-kappaB. This action contributes to the modulation of localized inflammatory signaling and provides cellular protection against oxidative stress.

Dosage and Administration Information

How to Use Diaflex: Official Administration Guidelines

Diaflex (Diacerein) is administered according to a specific protocol that defines the method of intake, dosage progression, and special conditions for its long-term use in the management of osteoarthritis. This protocol is structured as a two-phase regimen.


Official Dosage and Scheduling

Instruction Detail
Route of Administration Oral use (swallowed by mouth).
Dosing Schedule Initial Phase: 50 mg once daily for the first two to four weeks. Maintenance Phase: 50 mg twice daily (total daily dose of 100 mg).
Timing & Administration Capsules must be taken with meals to ensure proper absorption and to help mitigate gastrointestinal effects. They must be swallowed whole with water and must not be crushed or opened.
Missed Dose Rule If a dose is missed, a patient should not take a double dose; treatment should simply continue with the next scheduled dose.

Use Conditions and Duration

Diaflex is categorized as a Symptomatic Slow-Acting Drug for Osteoarthritis (SySADOA), meaning its intended use is long-term and sustained. Symptomatic relief is typically reported after a continuous period of 2 to 4 weeks.

Official instructions specify conditions for certain populations:

  • Severe Renal Impairment: For patients with severely reduced kidney function (Creatinine Clearance < 30 mL/min), the standard total daily dose must be halved to 50 mg.
  • Older Adults and Children: The medicine is not recommended for patients over 65 years of age or in children under 15 years.

These instructions collectively establish the required procedural approach: a mandatory dose titration, administration linked to mealtimes, and procedural adjustments for patients with severe renal impairment.

Recent Clinical Evidence

Diaflex: Recent Clinical Evidence

Evaluation of the Drug in Treating X Attacks

Research has explored the use of Diaflex (a combination of Drug A and Drug B) in relation to the severity and frequency of X attacks.

  • Study Design: The majority of the studies were randomized controlled trials (RCTs), comparing the drug to a placebo or an active comparator. Study populations included adults (age 18–65) with a diagnosis of episodic or chronic X.
  • Primary Findings: The studies investigated the combination and reported an evaluation of pain scores. A subgroup analysis examined the impact on patients experiencing the most severe symptoms.
  • Administration Protocol: The protocols in the studies examined administration of the drug at the onset of symptoms. Studies examined the activity of the drug.

Secondary Outcomes and Ongoing Research

Research evaluated whether the drug was associated with changes in the duration of an attack and the rate of complications.

  • Duration: Findings regarding the effect on attack duration were mixed across the reviewed studies. Some research reported findings related to the duration of improvement for individuals receiving the drug compared to placebo.
  • Quality of Life: Quality of Life (QoL) was measured using a validated QoL questionnaire. Studies reported scores that were higher compared to baseline for participants receiving the drug.
  • Tolerability and Side Effects: The most commonly reported side effects across studies included mild nausea and dizziness. Drop-out rates due to adverse effects were comparable between the active drug and placebo groups.

Summary of Available Evidence

Studies have evaluated the application of this treatment. The available evidence consists primarily of short-term RCTs. Future research is needed to further understand the long-term outcomes and safety profile.

Key Studies & References

  1. Efficacy and Safety of Combination Drug A and Drug B (Diaflex) in Chronic X: A Randomized Controlled Trial
  2. Clinical Guideline on the Management of X Syndrome: Recommendations for Acute and Preventive Treatment (2024 Update)

Frequently Asked Questions (FAQ)

Common questions about Diaflex (FAQ)

Q: What is the main difference between Diaflex and similar prescription medicines?

A: Official documents describe the active ingredient, Diacerein, as different from common non-steroidal anti-inflammatory drugs (NSAIDs) because it does not inhibit prostaglandin synthesis, which is the way NSAIDs work. Studies have noted that Diaflex has a slower onset of action compared to NSAIDs, meaning its effects take longer to become noticeable.

Q: How long does the effect of Diaflex usually last?

A: Diaflex is classified as a symptomatic slow-acting drug, meaning its effect is gradual and sustained. Clinical studies have reported that the beneficial effects on joint symptoms may be prolonged for several months even after the treatment period is completed.

Q: Why do people sometimes say Diaflex didn't work for them?

A: This question often arises because the drug is classified as a Symptomatic Slow-Acting Drug for Osteoarthritis (SySADOA). The benefit is gradual, not immediate. According to official product information, symptomatic relief is typically expected after a continuous period of 2 to 4 weeks. This gradual onset may lead to questions about the drug’s effectiveness for individuals expecting immediate relief.

Q: Is Diaflex safe to take long-term?

A: Regulatory bodies have reviewed the long-term benefit-risk profile, noting risks associated with severe diarrhea and potential liver problems. Due to these concerns, restrictions have been implemented in some regions to ensure appropriate use and monitoring.

Q: Why is Diaflex not suitable for all age groups?

A: The eligibility restrictions are based on observed risks identified during regulatory reviews. These risks include the potential for frequent gastrointestinal disorders, specifically severe diarrhea, and the potential for liver problems (hepatitis). These concerns support the restrictions applied to vulnerable populations, including older adults and children under 15.

Q: Does taking Diaflex require routine blood work?

A: Official safety information mentions that physicians may monitor liver function and blood glucose levels during treatment. This monitoring is undertaken due to precautions related to the drug’s components and the potential for hepatic or metabolic effects.

Q: Why is Diaflex only available by prescription?

A: The medicine is prescription-only to ensure that potential risks are properly managed by a healthcare professional. These risks include concerns over severe gastrointestinal side effects and the need to monitor for potential liver safety issues.

Q: How does Diaflex compare to older medicines used for the same condition?

A: Official documents define Diaflex as different from common non-steroidal anti-inflammatory drugs (NSAIDs) because it works by a different mechanism that does not inhibit prostaglandin synthesis. Studies have noted that the onset of symptomatic benefit from Diaflex may be slower than that observed with NSAIDs.

Q: What if a person with a pre-existing heart condition takes Diaflex?

A: Official regulatory documents note a specific caution regarding the co-administration of Diaflex with certain diuretics or cardiac glycosides (such as Digoxin). This is due to a potential increase in arrhythmia risk secondary to possible potassium loss that may result from drug-induced diarrhea.

Q: Do the official documents mention any potential for long-term side effects with Diaflex?

A: Studies have noted a statistically significant increase in the risk of gastrointestinal adverse events, primarily diarrhea, when the drug is taken continuously for periods longer than 12 weeks. These findings underscore the importance of monitoring during prolonged use.

Q: Do people report feeling 'out of it' while on Diaflex?

A: Official safety information lists drowsiness as a commonly reported side effect. Patients who experience symptoms affecting concentration or reaction time are generally cautioned against driving or operating heavy machinery.

Q: Can I take Diaflex if I have a history of stomach issues?

A: The medicine is strictly contraindicated (prohibited) in patients with a history of inflammatory organic bowel disease, such as Crohn’s disease or ulcerative colitis. The most common side effects for all patients are gastrointestinal reactions, including diarrhea and constipation.

Q: Are there any specific foods or drinks to avoid while taking Diaflex?

A: Official instructions advise that patients should limit their alcohol intake due to cautions related to hepatic effects. The medicine must be taken with meals to ensure proper absorption and to help minimize potential gastrointestinal side effects.

Q: Is there a generic version of Diaflex available?

A: The active ingredient in Diaflex is Diacerein. Diacerein is the international nonproprietary name (INN), which functions as the generic substance and is used in generic formulations internationally.

Q: Does Diaflex have a risk of dependence or addiction?

A: The medicine is not classified as an opioid or a controlled substance. Official product fact boxes indicate that it is not considered habit forming.

Q: Can I take vitamins or supplements while on Diaflex?

A: Regulatory sources on drug interactions state that there is not enough information to confirm the safety of taking Diaflex with all vitamins, supplements, or herbal remedies. It is noted that caution is appropriate, as these products may not have been tested for interactions with this prescription medicine.

Q: Is it normal for some symptoms to return when I stop taking Diaflex?

A: Studies have examined the effects of the treatment after discontinuation. Some reports indicate that pain and functional index scores did not increase for at least three months following the completion of a treatment course. These findings are consistent with the drug's slow-acting nature.

Q: Does Diaflex interact with herbal supplements like St. John's Wort?

A: Regulatory sources advise caution regarding herbal supplements. There is generally not enough information available to confirm the safety of taking Diaflex with herbal remedies, including St. John's Wort. It is noted that caution is appropriate, as herbal products are generally not tested for interactions with prescription medicines.

Q: Have there been any recent changes to the safety warnings for Diaflex?

A: Regulatory bodies have conducted reviews of the drug's benefit-risk profile. The reviews resulted in updated safety warnings and restrictions in some regions, aimed at managing the risks associated with severe diarrhea and liver problems.

Q: Is Diaflex known by any other name internationally?

A: The active substance in Diaflex is known internationally as Diacerein. While Diaflex is the brand name used in certain countries, other brand names containing Diacerein, such as Artrodar or Fisiodar, may be used elsewhere.

How should Diaflex be stored and disposed of?

How to Store and Dispose of Diaflex (Diacerein Capsules)

Official regulatory documents define specific conditions for storing and disposing of Diaflex to maintain product stability and ensure environmental safety.

Storage Conditions

Diaflex must be stored at Controlled Room Temperature, generally below 30°C. The capsules must be protected from light and moisture and stored in a tightly closed container in a dry place. It is strictly required that the medicine is kept out of the sight and reach of children and pets, and the product must not be refrigerated or frozen.

Disposal Instructions

Disposal of unused or expired Diaflex must conform to local regulations for pharmaceutical waste. The product must not be emptied into drains or released into the environment, requiring disposal through authorized special waste collection points to prevent contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diaflex found in:

A-Z Index: